A novel protease-activated receptor 1 inhibitor from the leech Whitmania pigra
Pharmacology article published in Chinese Journal of Natural Medicines (2019)
Abstract
Whitmania pigra has been used as a traditional Chinese medicine (TCM) for promoting blood circulation, alleviating blood coagulation, activating meridians and relieving stasis for several hundred years. However, the therapeutic components of this species, especially proteins and peptides were poorly exploited. Until now only a few of them were obtained by using chromatographic isolation and purification. In recent decade, transcriptome techniques were rapidly developed, and have been used to fully reveal the functional components of many animal venoms. In the present study, the cDNA of the salivary gland of Whitmania pigra was sequenced by illumina and the transcriptome was assembled by using Trinity. The proteome were analysed by LC-MS/MS. Based on the data of the transcriptome and the proteome, a potential antiplatelet protein named pigrin was found. Pigrin was cloned and expressed using P. pastoris GS115. The antiplatelet andantithrombotic bioactivities of pigrin were tested by using aggregometer and the rat arterio-venous shunt thrombosis model, respectively. Thebleeding time of pigrin was measured by a mice tail cutting method. The docking of pigrin and protease-activated receptor 1 (PAR1) or collagen were conducted using the ZDOCK Server. Pigrin was able to selectively inhibit platelet aggregation stimulated by PAR1 agonist and collagen. Pigrin attenuated thrombotic formation in vivo in rat, while did not prolong bleeding time at its effective dosage. There are significant differences in the key residues participating in binding of Pigrin-Collagen complex from Pigrin-PAR1 complex. In conclusion,a novel PAR1 inhibitor pigrin was found from the leech Whitmania pigra. This study helped to elucidate the mechanism of the leech for the treatment of cardiovascular disorder.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Combined transcriptome and proteome of Whitmania pigra salivary glands identifies pigrin, a novel PAR1 inhibitor that selectively inhibits PAR1-agonist and collagen-stimulated platelet aggregation in vivo without prolonging bleeding time.
Warum dies für die Hirudotherapie relevant ist
Diese Studie identifizierte Pigrin, einen neuartigen Inhibitor des Protease-aktivierten Rezeptors 1 (PAR1) aus dem Blutegel Whitmania pigra, durch kombinierte Transkriptom- und Proteom-Analyse mit anschließender rekombinanter Expression in Pichia pastoris. Funktionelle Tests zeigten, dass Pigrin selektiv die durch PAR1-Agonisten und Kollagen stimulierte Thrombozytenaggregation hemmte, die Thrombusbildung in einem arteriovenösen Shunt-Modell der Ratte abschwächte und bei seiner wirksamen antithrombotischen Dosierung die Blutungszeit bei Mäusen nicht verlängerte. Für das Gebiet der ASH stellt Pigrin eine neu entdeckte bioaktive Substanz aus Blutegeln mit antithrombotischen Eigenschaften dar und erweitert das bekannte pharmakologische Repertoire des Blutegel-Sekretoms. Einschränkung: Es handelt sich um eine präklinische Studie mit In-vitro-Assays und Nagetier-Tiermodellen; die Befunde wurden nicht in klinischen Studien am Menschen validiert, und das Abstract geht nicht auf die Hirudotherapie-Praxis mit lebenden Blutegeln ein.
Zitation
A novel protease-activated receptor 1 inhibitor from the leech Whitmania pigra.
Ren SH, Liu ZJ, Cao Y et al. · Chinese journal of natural medicines, 2019
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026